Author Archives: Marisa Wexler

Biogen Discontinues Development of Cinpanemab

Due to negative clinical trial findings, Biogen has discontinued the development of cinpanemab (BIIB054), an investigational medication intended to treat Parkinson’s disease, the company announced in its 2020 investors report. Cinpanemab is a human-derived antibody that targets alpha-synuclein, thought to be one of the key hallmarks of Parkinson’s disease. In the…

New Mental Health Guidelines in UK Highlight Lack of Research, Services

New guidelines published by The British Psychological Society highlight the lack of mental health research and services for people living with Parkinson’s disease and other neurodegenerative conditions, and offers evidence-based recommendations for health professionals to help better serve patients. “We hope that our guidelines will add to…

Disturbed Sleep Common, But Not Tied to Patient’s Sex or Disease Stage

Neither a patient’s sex nor the degree of disease progression substantially affects the manifestations of sleep disturbances in Parkinson’s disease, a study reports. More research into this “very common” and life-affecting problem — and into other non-motor symptoms — of Parkinson’s is needed, its researchers said. The study,…

Array of Motor Symptoms Seen to Most Bother Patients, Changing Over Time

As Parkinson’s disease progresses, the symptoms that are most bothersome to patients change, a survey study reports. Specifically, hallmark motor symptoms like dyskinesia (involuntary movements) and those affecting walking, balance and speech were mentioned most by those with longer disease duration, while tremor ranked high among people at earlier stages. The…

Genetic Testing and Counseling Mostly Seen Favorably in Study

Most people who undergo genetic testing and counseling related to Parkinson’s disease are satisfied with their experience and feel no substantially adverse psychological effects, a study reported. However, its findings also indicated that people with diagnosed Parkinson’s, or in whom Parkinson’s-linked mutations are identified, are more likely to be…

MJFF Announces 5 Parkinson’s Clinical Trials in Need of Recruits

Participants are now being recruited for several clinical trials testing investigational treatments for Parkinson’s disease, The Michael J. Fox Foundation (MJFF) announced. Clinical trials are well-designed experiments conducted on human participants. Since such trials actually test a treatment in people, these studies are essential for understanding whether a given…

FDA Approves Nuplazid for Capsule Sprinkling

The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Nuplazid (pimavanserin) that will allow the medication to be taken more easily by Parkinson’s patients who have difficulty swallowing. Nuplazid, by Acadia Pharmaceutical, is an oral medication that was approved…

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums